Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma

Josep M. Llovet

doi:10.1038/s41571-025-01055-5

Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma

Josep M. Llovet

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

Immune-checkpoint inhibitors have revolutionized the management of hepatocellular carcinoma. Currently, anti-PD-(L)-1 antibodies combined with either bevacizumab or anti-CTLA4 antibodies are the standard of care for advanced-stage tumours. Now, two phase III studies (CheckMate 9DW and APOLLO) have reported positive survival results in the first-line setting, although with distinct implications for clinical practice.

Original language	English
Pages (from-to)	625-626
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	22
Issue number	9
DOIs	https://doi.org/10.1038/s41571-025-01055-5
State	Published - Sep 2025

Access to Document

10.1038/s41571-025-01055-5

Cite this

@article{e6cd502e131e4551aa6bb6fa80cbf1f0,

title = "Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma",

abstract = "Immune-checkpoint inhibitors have revolutionized the management of hepatocellular carcinoma. Currently, anti-PD-(L)-1 antibodies combined with either bevacizumab or anti-CTLA4 antibodies are the standard of care for advanced-stage tumours. Now, two phase III studies (CheckMate 9DW and APOLLO) have reported positive survival results in the first-line setting, although with distinct implications for clinical practice.",

author = "Llovet, \{Josep M.\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2025.",

year = "2025",

month = sep,

doi = "10.1038/s41571-025-01055-5",

language = "English",

volume = "22",

pages = "625--626",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma

AU - Llovet, Josep M.

N1 - Publisher Copyright: © Springer Nature Limited 2025.

PY - 2025/9

Y1 - 2025/9

N2 - Immune-checkpoint inhibitors have revolutionized the management of hepatocellular carcinoma. Currently, anti-PD-(L)-1 antibodies combined with either bevacizumab or anti-CTLA4 antibodies are the standard of care for advanced-stage tumours. Now, two phase III studies (CheckMate 9DW and APOLLO) have reported positive survival results in the first-line setting, although with distinct implications for clinical practice.

AB - Immune-checkpoint inhibitors have revolutionized the management of hepatocellular carcinoma. Currently, anti-PD-(L)-1 antibodies combined with either bevacizumab or anti-CTLA4 antibodies are the standard of care for advanced-stage tumours. Now, two phase III studies (CheckMate 9DW and APOLLO) have reported positive survival results in the first-line setting, although with distinct implications for clinical practice.

UR - https://www.scopus.com/pages/publications/105009529942

U2 - 10.1038/s41571-025-01055-5

DO - 10.1038/s41571-025-01055-5

M3 - Comment/debate

AN - SCOPUS:105009529942

SN - 1759-4774

VL - 22

SP - 625

EP - 626

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 9

ER -

Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma

Abstract

Access to Document

Fingerprint

Cite this